Enzon Pharmaceuticals, Inc. (EZ1.SG)
- Previous Close
0.0710 - Open
0.0710 - Bid 0.0655 x 2500000
- Ask 0.0990 x 2500000
- Day's Range
0.0710 - 0.0710 - 52 Week Range
0.0485 - 0.2300 - Volume
0 - Avg. Volume
95 - Market Cap (intraday)
6.181M - Beta (5Y Monthly) 0.26
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 30, 2019
- 1y Target Est
--
Enzon Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the sale of its patented drug product, PegIntron. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.
enzon.comRecent News: EZ1.SG
View MorePerformance Overview: EZ1.SG
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EZ1.SG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EZ1.SG
View MoreValuation Measures
Market Cap
6.18M
Enterprise Value
-33.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
226.84
Price/Book (mrq)
3.02
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
2,992.31%
Return on Assets (ttm)
-1.75%
Return on Equity (ttm)
1.70%
Revenue (ttm)
26k
Net Income Avi to Common (ttm)
-497k
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
46.86M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-827.38k